<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02648906</url>
  </required_header>
  <id_info>
    <org_study_id>DWB_GTM001</org_study_id>
    <nct_id>NCT02648906</nct_id>
  </id_info>
  <brief_title>A Clinical Trial for an Evaluation of Choline Alfoscerate and Donepezil for Cognitive Improvements of Patients With Cerebrovascular Injury in Alzheimer Patients</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daewoong Pharmaceutical Co. LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daewoong Pharmaceutical Co. LTD.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate efficacy and safety of Choline alfoscerate and
      Donepezil for cognitive improvements of patients with cerebrovascular injury in Alzheimer
      patients
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2015</start_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change of ADAS-cog score compared with Baseline</measure>
    <time_frame>48 weeks</time_frame>
    <description>Primary outcome will be evaluated with ADAS-cog questionnaire 48 weeks after taking investigational product.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">128</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>Choline alfoscerate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: Choline alfoscerate and Donepezil
concomitant administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Drug: Donepezil only</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Choline alfoscerate</intervention_name>
    <arm_group_label>Choline alfoscerate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 56~90 male and female

          2. Mini-Mental State Evaluation (MMSE) between 24 and 12

          3. Score â‰¥ 2 at the New Rating Scale for Age-related White Matter Changes (ARWMC), the
             rating scale of cerebral ischemic injury evaluated with MRI

          4. Score 0.5, 1, 2 at CDR

          5. presence of at least two of the following vascular risk factors: hypertension,
             diabetes, obesity, ischemic heart disease, dyslipidemia, hyperhomocysteinemia,
             smoking, previous cerebrovascular events and familiar history of
             cardio-cerebrovascular diseases.

          6. donepezil 10mg from 3 months ago, dose not changed during clinical trials

          7. A subject who provided written informed consent to participate in this study and
             cooperative with regard to compliance with study related constraints

        Exclusion Criteria:

          1. Subjects allergic to or sensitive to the Investigational Product or applicable
             ingredients

          2. subject who has taken below medication 1 month before screening 1) Cholinesterase
             Inhibitors 2) NMDA receptor antagonists 3) blood circulation supplements 4)
             Acetyl-L-Carnitines 5) Nicergoline 6) Subject who has taken another medication that
             can affect the result of primary outcome

          3. subject that can't be evaluated with ADAS-cog, MMSE, NPI, ADL, CDR, Attention
             Questionnaire Scale etc.

          4. Asthma, COPD

          5. Decompensated heart disease

          6. Chronic renal failure or chronic liver disease

          7. Malignant tumor

          8. Subject that cant' be followed up for 12 months after Investigational drug was taken.

        9 Subjects who are pregnant, lactating or who plan to be pregnant during the clinical
        period or females of child bearing years who do not use available contraceptive methods 10.
        Subject who has taken other clinical or licensed medication from another clinical trial
        within 30 days prior screening period 11.Other subjects who are deemed not to be
        appropriate for this clinical study in the discretion of investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>56 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jina Song</last_name>
    <phone>82-2-550-8865</phone>
    <email>jnsong058@daewoong.co.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Sungnam</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 5, 2016</study_first_submitted>
  <study_first_submitted_qc>January 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2016</study_first_posted>
  <last_update_submitted>November 1, 2016</last_update_submitted>
  <last_update_submitted_qc>November 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Donepezil</mesh_term>
    <mesh_term>Choline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

